Three currently circulating omicron subvariants of SARS-CoV-2 – including two that currently make up almost 50% of reported COVID-19 infections in the U.S. – are better at evading vaccine- and infection-generated neutralizing antibodies than earlier versions of omicron, new research suggests.
Though antiretroviral therapy has made HIV a manageable disease, people living with HIV often suffer from chronic inflammation. This can put them at an increased risk of developing comorbidities such as cardiovascular disease and neurocognitive dysfunction, impacting the longevity and quality of their lives.
More than 20 UT Southwestern Medical Center scientists are among the 2022 Highly Cited Researchers listed in the top 1% of researchers from across the globe
UC San Diego researchers expand and deepen understanding of how genetic aberrations fuel human papilloma virus-negative head and neck cancers and, potentially, provide paths to further refinement and improvement of immune checkpoint inhibitors for HPV-negative head and neck cancers.
A Ludwig Cancer Research study has revealed a single protein expressed at high levels by cancer cells across a broad range of malignancies that erects a multifaceted barrier to anti-cancer immune responses in mouse models of cancer and so shields tumors from immune detection and destruction.
Two studies published by The BMJ today provide up to date evidence on the effectiveness of both currently licensed and possible covid-19 treatments under everyday (‘real world’) conditions, helping to shed more light on whether these drugs can prevent people from becoming seriously ill.
Researchers at Karolinska Institutet in Sweden have shown that patients with acute COVID-19 infection have increased levels of the cytokine IL-26 in their blood.
Chronic alcohol misuse including Alcohol Use Disorder (AUD), is an overlooked risk factor for severe or fatal COVID-19, according to a review of medical and scientific studies.
COVID-19 reactivated viruses that had become latent in cells following previous infections, particularly in people with chronic fatigue syndrome, also known as ME/CFS.
The University of Texas MD Anderson Cancer Center today announced a $10 million gift to the James P. Allison Institute from the Andrew Sabin Family Foundation and Andrew “Andy” Sabin, a senior member of the MD Anderson Cancer Center Board of Visitors (BOV). The gift is the philanthropist’s second multimillion-dollar commitment to MD Anderson in less than 10 years.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising targeted therapy combination for patients with relapsed/refractory acute myeloid leukemia (AML), a link between the gut microbiome and therapy-related neutropenic fever, a novel therapeutic target for immunotherapy-related colitis, a telementoring model for training providers on cervical cancer prevention in limited-resource areas, a new understanding of the prognostic value of RUNX1 mutations in AML, and insights into the effects of opioid use on the pain sensitivity pathway.
COVID-19 reactivated viruses that had become latent in cells following previous infections, particularly in people with chronic fatigue syndrome, also known as ME/CFS.
The researchers discovered that T-cells recognizing the cardiac antigen α-myosin are the mechanism for this complication, setting the framework to identify biomarkers so at-risk patients can be recognized and medical strategies developed for them to tolerate the immunotherapy. Their findings are reported Nov. 16 in Nature.
In a small study, Johns Hopkins Kimmel Cancer Center researchers successfully trained a machine learning algorithm to predict, in hindsight, which patients with melanoma would respond to treatment and which would not respond.
The 2022 "Highly Cited Researchers" list from Clarivate includes several La Jolla Institute for Immunology (LJI) scientists well versed in lay friendly communication. These experts are ready to share exciting new research with media and podcast outlets. Contact [email protected] to set up an interview and make arrangements for high quality audio capture.
Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system’s T cells to attack tumor cells. Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement. In a paper published online today in The Journal of Clinical Investigation (JCI), scientists at Albert Einstein College of Medicine describe findings that could bolster the effectiveness of immune-checkpoint therapy.
Researchers at the Icahn Mount Sinai have identified 35 genes that are particularly highly expressed in people with long-term Lyme disease. These genes could potentially be used as biomarkers to diagnose patients with the condition, which is otherwise difficult to diagnose and treat. The findings, published November 15 in the journal Cell Reports Medicine, may also lead to new therapeutic targets. The study is the first to use transcriptomics as a blood test to measure RNA levels in patients with long-term Lyme disease.
An immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, lurking in cells only to erupt anew, researchers at Duke Health report.
Hosted by Chulalongkorn University the APRU APEC University Leaders' Forum 2022 is the first post-pandemic in-person APEC meeting held to foster high-level dialogue between CEOs, policy leaders, university presidents, and top researchers. This event begins Nov 15 at 9 PM EST.
A scalpel-free, high-tech form of brain surgery pioneered at UVA Health offers long-term relief for patients with essential tremor, a common movement disorder, a five-year review shows.
Every day, one person in Switzerland is diagnosed with multiple sclerosis. MS is an autoimmune disease in which the body’s own immune system attacks the myelin sheath of the nerve cells in the brain and spinal cord.
For the first time, scientists have used CRISPR technology to insert genes that allow immune cells to focus their attack on cancer cells, potentially leaving normal cells unharmed and increasing the effectiveness of immunotherapy.
Research shows that incidences of Kaposi’s sarcoma among people living with HIV have fallen significantly over the past two decades, but a new evaluation of data led by researchers at UTHealth Houston highlights a significant disparity among one particular demographic – young Black men in the American South.
A team of researchers at The University of Texas MD Anderson Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest this adaptable immune conversion approach has the potential for broad application across many cancer types.
Rejuvenating the immune cells that live in tissues surrounding the brain improves fluid flow and waste clearance from the brain — and may help treat or even prevent neurodegenerative diseases such as Alzheimer’s and Parkinson’s, according to a study by researchers at Washington University School of Medicine in St. Louis.
This special edition features upcoming presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, including immunotherapy advances in human papillomavirus (HPV)-positive head and neck cancers, microbiome signatures linked with specialized immune-cell clusters, and promising early activity from novel immunotherapy drugs in advanced melanoma and colorectal cancer.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, showed that discontinuing methotrexate for 1 week after seasonal influenza vaccination provided the same seroprotection as a 2 week discontinuation period in patients with RA.
Some cancer cells can deploy parallel mechanisms to evade the immune system’s defences as well as resist immunotherapy treatment, according to a new study from the Garvan Institute of Medical Research.
RUDN scientists have shown the possibility of treating endometriosis with the help of macrophages - immune cells that help fight foreign agents. A new approach in the future can replace the standard treatment with surgery.
Scientists from Trinity College Dublin have unearthed a secret that may explain why some people are able to resist viral infections, having screened the immune systems of women exposed to hepatitis C (HCV) through contaminated anti-D transfusions given over 40 years ago in Ireland.
Mount Sinai and Memorial Sloan Kettering Cancer Center (MSK) researchers have identified therapies that can help patients with the blood cancer multiple myeloma who try an immunotherapy known as CAR-T only to find their cancer coming back afterwards.
Insulin injections to treat Type 1 diabetes could become a thing of the past, but finding the cure faces many challenges. Although transplanting insulin-producing cells represents a promising approach, this cell therapy requires immunosuppression to prevent rejection. Georgia Tech researchers have developed a new biomaterial called iTOL-100 that could cure Type 1 diabetes by inducing immune acceptance of curative transplanted cells without immunosuppression.
As researchers glean new insights into the dynamic inner world of the human immune system, it has become increasingly clear that mitochondria are critical regulators of how our bodies respond to disease.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Patients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than those who haven't received such therapies in the three months before their COVID diagnosis, show findings in a new study by researchers at Dana-Farber Cancer Institute, and across the U.S., Canada, and Mexico. Researchers found worse outcomes in both the disease itself as well as the fierce immune response that sometimes accompanies it.
A combination of two types of cancer-fighting treatments – the immunotherapy agent pembrolizumab and a nanoparticle-bound form of the chemotherapy drug paclitaxel – may provide an urgently needed new treatment approach for patients who do not respond to or can't receive standard chemotherapy for advanced urothelial cancers, reports a preliminary study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Inflammation and increased mucus production are typical symptoms of worm infections and allergies. This immune response involves our innate immune cells, but their exact functions are not yet fully understood.
A new model for understanding which patients with sepsis, Covid-19 and influenza have immune dysfunction and are more likely to suffer poor outcomes has been developed by researchers at the Wellcome Sanger Institute, the University of Oxford, Queen Mary University, Imperial College and their collaborators.
The Flow Cytometry Core at Sanford Burnham Prebys is getting a new piece of state-of-the-art research equipment, thanks to a grant from the National Institutes of Health.
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco (UCSF) has discovered the underlying cause of gender differences in immunotherapy-associated myocarditis after immune checkpoint inhibitor (ICI) treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
In the past several years, myocarditis has been of public interest because of cases associated with vaccines for SARS-CoV2 or related conditions. Another form of myocarditis has been linked to immune checkpoint inhibitors (ICIs) used in cancer care. ICI-induced myocarditis is a potentially fatal side effect of ICI usage, and it appears that the adverse cardiac effects may disproportionally impact female patients. This finding is in contrast to other forms of myocarditis, with more cases reported in male patients.
Nas seis décadas em que o transplante de sangue e medula tem sido usado para tratar pacientes com câncer no sangue, esse tratamento experimental tornou-se uma ferramenta vital de combate ao câncer. A Mayo Clinic, em Rochester, Minnesota, está celebrando a marca de 10 mil transplantes sanguíneos e de medula usados para o tratamento de cânceres sanguíneos e de doenças relacionadas.
مدينة روتشستر، ولاية مينيسوتا. - على مدار الستة عقود الماضية منذ بداية استخدام عمليات زراعة الدم والنخاع لعلاج المرضى المصابين بسرطان الدم، أصبح هذا العلاج التجريبي أداة حيوية لمكافحة السرطان. تحتفل مايو كلينك في مدينة روتشستر بولاية مينيسوتا بإجراء 10,000 عملية زراعة دم ونخاع لعلاج سرطانات الدم والاضطرابات ذات الصلة.